Nexway Announces Departure of Chief Strategy Officer Casey Potenzone
Nexway SAS, an e-commerce and payments leader, today announced that Chief Strategy Officer Casey Potenzone will depart from the company on December 31.
Mr. Potenzone joined Nexway in 2014 as head of sales operations and was appointed Chief Strategy Officer in 2017. He has since demonstrated strong leadership as a member of the Executive Board, implementing new company-wide strategy and overseeing the sales, account management and marketing teams.
“I am very grateful to Casey for his service and contribution to the company, “ said CEO Victor Iezuitov. “Casey has played a key role in the management of our business during his tenure and was vital in winning new customers.”
Mr. Iezuitov continued, “Casey led strategic initiatives to steer the company into the payment orchestration space, allowing us to structure a better positioned product. A genuine and endearing member of the team, Casey’s ceaseless commitment to the cause during the COVID-19 pandemic has helped Nexway manage the disruption.”
Mr. Potenzone said, “These past six years with Nexway have been an exciting and challenging experience. I am proud of the progress the company has made in its evolution. Following the successful transition to new ownership, Nexway is now poised for significant growth in this unprecedented time of e-commerce adoption.”
Nexway will continue in its strategy to facilitate e-commerce transformation and support companies in their ambitions of rapid growth.
The Executive Board of Nexway will lead the company’s commercial operations until a new team leader is appointed.
About Nexway
Nexway SAS is a leading e-commerce and payment player. Combining technology and managed services, Nexway helps online businesses scale, grow, and thrive. Nexway’s expertise in subscriptions, local payments, fraud prevention and reseller management enables customers to transform their purchasing experience and accelerate sales. Founded in 2002 and headquartered in Paris–La Défense, France, Nexway has subsidiaries in the USA, Brazil, Italy, Spain, Poland and Japan. Companies who rely on Nexway include FNAC-Darty™, Amazon™, Kaspersky™, Adobe™, Avast™, Bit Defender™, TakeTwo, and hundreds more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201124005491/en/
Contact information
PR contact for Nexway:
Cécile Abescat
Marketing Team Manager
cabescat@nexway.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Former Wasabi EMEA VP Richard Czech Joins Leviia to Lead European Channel Expansion18.9.2025 12:00:00 EEST | Press release
Leviia, the French cloud storage provider with more than one million users and 1,000 enterprise customers, today announces a major step in its growth strategy: the expansion of its S3 storage operations across Europe. To lead this initiative, Leviia has appointed Richard Czech, former Vice President EMEA at Wasabi, as Chief Business Development Officer. Czech will drive market development and scale Leviia’s partner ecosystem across Europe, building on the company’s successful go-to-market model in France. “Richard’s arrival reflects the scale of our ambitions in Europe,” said William Méauzoone, co-founder of Leviia. “He combines first-hand experience in scaling a major storage player with an exceptional understanding of the European channel landscape. ” “I’m excited to join Leviia and lead its European expansion,” said Czech. “Organizations face growing pressure to store data in sovereign, multi-site environments. Unlike non-European providers such as Amazon or Wasabi, Leviia is unique
Neumirna Therapeutics Appoints Ellen K. Donnelly as Chief Executive Officer18.9.2025 12:00:00 EEST | Press release
Neumirna Therapeutics, a biotechnology company developing RNA-based therapies for neurological diseases, today announced the appointment of Ellen K. Donnelly, Ph.D. as Chief Executive Officer. Ellen brings more than 20 years of leadership in neuroscience and rare diseases, spanning both global pharmaceutical companies and innovative biotech firms. She joins Neumirna from her role as CEO of Abliva AB, recently acquired by Pharming Group, and has previously led Modus Therapeutics and Souvien Therapeutics. Earlier in her career, Ellen spent nearly a decade at Pfizer Inc., where she held leadership roles in neuroscience research, clinical operations, portfolio management, and strategy. She holds a Ph.D. in Pharmacology & Neuroscience from Yale University. "Ellen combines scientific expertise with proven leadership in both biotech and pharma," said Luis Pareras, Chairman of the Board at Neumirna. "The Board is confident that under her guidance, Neumirna will continue to translate our innova
IQM and Scientek Corporation Sign Reseller Agreement to Boost Quantum Computing in Taiwan18.9.2025 11:11:00 EEST | Press release
IQM Quantum Computers and Scientek Corporation, a Taiwan-based reseller of scientific instruments and other high-technology products, today announced the signing of a strategic reseller agreement to accelerate the commercialisation of quantum computing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918110284/en/ IQM and Scientek Corporation sign reseller agreement The agreement follows the installation of IQM Spark, the first full-stack superconducting quantum computer at the Taiwan Semiconductor Research Institute (TSRI). Under the reseller agreement, Scientek will sell and promote IQM’s on-premises quantum computers and cloud solutions that meet the evolving needs of universities, research institutions, and enterprises. Combining Scientek's strong market presence and customer-centric approach in Taiwan with IQM’s quantum leadership, the collaboration will help Taiwanese businesses and research institutions to explore a
Acuity Knowledge Partners Acquires Ascent18.9.2025 10:30:00 EEST | Press release
Acuity Knowledge Partners (Acuity), a leading global provider of bespoke research, data management, analytics and AI solutions to the financial services sector, has announced that it has exchanged on the acquisition of Ascent. The transaction is expected to close on 30th September 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250915732380/en/ L-R: Stewart Smythe, Chief Executive Officer, Ascent; Jon O'Donnell, Chief Operating Officer, Acuity Knowledge Partners, and Robert King, Chief Executive Officer, Acuity Knowledge Partners This strategic move significantly expands Acuity's Data and Technology Services (DTS) division and its offering of technology and AI led services and solutions. Ascent, a leading European provider of AI-powered digital transformation services, supports over 170 clients globally, with 550 data, software, and cloud specialists operating across seven European jurisdictions. “Our acquisition of Asc
Almirall Presents Long‑Term Results from First Real‑World Dermatology Study Using WHO‑5 Well‑Being Index as Primary Endpoint in the treatment of Psoriasis at EADV 202518.9.2025 09:00:00 EEST | Press release
Almirall, S.A. (ALM) a global biopharmaceutical company focused on medical dermatology today announced new long-term results from the POSITIVE study, presented as a late-breaker at the 34th Congress of the European Academy of Dermatology and Venereology 2025 (EADV) in Paris. POSITIVE is the first RWE study in dermatology to use the World Health Organization Well-Being Index (WHO-5) as a primary endpoint. The selection of the abstract as a late breaker at the EADV congress highlights the importance of the findings of the POSITIVE study and its unique approach to evaluating the long-term holistic impact of an advanced treatment in patients with moderate-to-severe psoriasis, a condition that profoundly impairs social, psychological, and physical quality of life, impacting overall well-being1. Two‑Year Real‑World Results from POSITIVE The 24-month, multinational, phase IV observational study enrolled 785 adult patients with moderate-to-severe plaque psoriasis across nine European countries
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom